



BÖLÜM 11

COVID-19 VE TİROİD

Türkan PAŞALI KİLİT¹

GİRİŞ

Şiddetli akut solunum sendromu koronavirüs 2'nin (SARS-CoV-2) neden olduğu 2019 koronavirüs hastalığı (COVID-19) ilk olarak Çinde(Wuhan) ortaya çıkmıştır ve Dünya Sağlık Örgütü (DSÖ) tarafından 9 Mart 2020'de bir salgın olarak ilan edilmiştir. (1) COVID-19'un neden olduğu salgın ülkemizi ve dünyayı etkiledi ve etkilemeye devam etmektedir. Virüs yüzey glikoproteinleri (S1 ve S2), insan hücrelerine bağlanmakta, bağlanırken anjiyotensin dönüştürücü enzim 2 (ACE-2) reseptörünü kullanarak, hücre içine de transmembran serin proteaz 2 (TMPRSS2)'yi kullanarak geçmektedir. ACE-2'ye bağlanma afinitesi ve ACE-2 reseptör ekspresyonu hastalık klinik gidişinde önemli yer tutmaktadır. SARS-Cov-2 enfeksiyonu direk virüsün yaptığı hasarla ya da dolaylı olarak sistemik etkilerinin sonucu olarak endokrin sistemi olumsuz etkilemektedir. (2)

ACE-2 reseptörleri endokrin organ ve dokularda yaygın olarak bulunmaktadır. Bu durum endokrin sistemi SARS-CoV-2 için açık hedef haline getirmektedir. Bugüne kadar yapılan çalışmalar ve biriken veriler, SARS-CoV-2'nin doğrudan viral etki veya otoimmün mekanizmalar aracılığıyla endokrin organ ve dokularda hasara neden olabileceğini desteklemektedir. ACE-2 geninin en fazla eksprese olduğu dokulardan biri de tiroid dokusudur. Atipik akut/ subakut tiroidit tabloları daha sık görülmektedir.(3,4) Bu bölümünde, COVID-19 enfeksiyonunun endokrin sistem organı olan tiroid bezini ve tiroid hastalıklarına etkisi özetlenmiştir.

¹ Dr. Öğr. Üyesi, Kütahya Sağlık Bilimleri Üniversitesi, Tıp Fakültesi, İç Hastalıkları AD., turkandr@yahoo.com

KAYNAKLAR

1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available online at <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-COVID-19---11-march-2020>, Accessed date: 28.12.2021
2. Young MJ, Clyne CD, Chapman KE . Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2. *The Journal of endocrinology*, 2020;247(2):R45–R62. Doi.org/10.1530/JOE-20-0260
3. Pal R, Banerjee M (2020). COVID-19 and the endocrine system: exploring the unexplored. *Journal of endocrinological investigation*, 2020; 43(7): 1027–1031. Doi.org/10.1007/s40618-020-01276-8
4. Ersoy CÖ. COVID-19 ve endokrin Sistem Hastalıkları. İç: Heper C, ed. Bursa Tabip Odası Sürekli Tıp Eğitimi Pandemi Kitabı Temmuz 2020, multidisipliner COVID-19. Bursa: Stüdyo Star Ajans Ltd Şti; 2020: 407-27
5. Wei L, Sun S, Xu CH, et al. Pathology of the thyroid in severe acute respiratory syndrome. *Human pathology*, 2007;38(1): 95–102. Doi.org/10.1016/j.humpath.2006.06.011
6. Ding Y, He L, Zhang Q, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. *The Journal of pathology*, 2004;203(2): 622–630. Doi.org/10.1002/path.1560
7. Wei L, Sun S, Zhang J, et al. Endocrine cells of the adenohypophysis in severe acute respiratory syndrome (SARS). *Biochemistry and cell biology = Biochimie et biologie cellulaire*, 88(4): 723–730. Doi.org/10.1139/O10-022
8. Li H, Liu SM, Yu XH, et al. (2020). Coronavirus disease 2019 (COVID-19): current status and future perspectives. *International journal of antimicrobial agents*, 55(5):105951. Doi.org/10.1016/j.ijantimicag.2020.105951
9. Van den Berghe G. (2014). Non-thyroidal illness in the ICU: a syndrome with different faces. *Thyroid : official journal of the American Thyroid Association*, 24(10):1456–1465. Doi.org/10.1089/thy.2014.0201
10. Samuels MH (Effects of variations in physiological cortisol levels on thyrotropin secretion in subjects with adrenal insufficiency: a clinical research center study. *The Journal of clinical endocrinology and metabolism*, 2000;85(4): 1388–1393. Doi.org/10.1210/jcem.85.4.6540
11. Chen M, Zhou W, Xu W. Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study. *Thyroid : official journal of the American Thyroid Association*, 31(1): 8–11. <https://doi.org/10.1089/thy.2020.0363>
12. Tan T, Khoo B, Mills EG, et al. Association between high serum total cortisol concentrations and mortality from COVID-19. *The lancet. Diabetes & endocrinology*, (2020);8(8):659–660. Doi.org/10.1016/S2213-8587(20)30216-3
13. Lazartigues E, Qadir MMF, Mauvais-Jarvis F. Endocrine Significance of SARS-CoV-2's Reliance on ACE2. *Endocrinology*, 2020; 161(9): bqaa108. Doi.org/10.1210/endo/bqaa108
14. Gavriatopoulou M, Korompoki E, Fotiou D, et al. Organ-specific manifestations of COVID-19 infection. *Clinical and experimental medicine*, 20(4): 493–506. Doi.org/10.1007/s10238-020-00648-x
15. Khoo B, Tan T, Clarke SA, et al. Thyroid Function Before, During, and After COVID-19. *J Clin Endocrinol Metab*. 2021; 23:106(2):e803-e811. Doi: 10.1210/clinem/dgaa830
16. Pashkovska NV. Pseudothyroid dysfunction in clinical practice: how to avoid diagnostic errors. *Mižnarodnij endokrinologičnij žurnal*.2018;14(4):344-353. Doi:10.22141/2224 0721.14.4.2018.140188
17. Yao XH, Li TY, He ZC, et al. *Zhonghua bing li xue za zhi = Chinese journal of pathology*, 2020; 49(5): 411–417. <https://doi.org/10.3760/cma.j.cn112151-20200312-00193>

18. Hanley B, Naresh KN, Roufousse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. *The Lancet. Microbe*, 2020; 1(6): e245–e253. [https://doi.org/10.1016/S2666-5247\(20\)30115-4](https://doi.org/10.1016/S2666-5247(20)30115-4)
19. Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis. *The lancet. Diabetes & endocrinology*, 2020;8(9):739–741. [Doi.org/10.1016/S2213-8587\(20\)30266-7](https://doi.org/10.1016/S2213-8587(20)30266-7)
20. Brancatella A, Ricci D, Cappellani D, et al. Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series. *J Clin Endocrinol Metab*. 2020; 1;105(10):dgaa537. [Doi: 10.1210/clinem/dgaa537](https://doi.org/10.1210/clinem/dgaa537)
21. Mattar S, Koh S, Rama Chandran S, et al Subacute thyroiditis associated with COVID-19. *BMJ case reports*, 2020; 13(8): e237336. [Doi.org/10.1136/bcr-2020-237336](https://doi.org/10.1136/bcr-2020-237336)
22. Lania, A, Sandri MT, Cellini M, et al Thyrotoxicosis in patients with COVID-19: the TH-YRCOV study. *European journal of endocrinology*, 2020; 183(4); 381–387. [Doi.org/10.1530/EJE-20-0335](https://doi.org/10.1530/EJE-20-0335)
23. Ruggeri RM, Campenni A, Deandreis D, et al SARS-COV-2-related immune inflammatory thyroid disorders: facts and perspectives. *Expert review of clinical immunology*, 2021; 17(7), 737–759. [Doi.org/10.1080/1744666X.2021.1932467](https://doi.org/10.1080/1744666X.2021.1932467)
24. Pal R COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications. *Endocrine*, 2020; 68(2): 251–252. [Doi.org/10.1007/s12020-020-02325-1](https://doi.org/10.1007/s12020-020-02325-1)
25. Antonelli A, Ferrari SM, Ragusa F, et al. Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. *Best practice & research. Clinical endocrinology & metabolism*, 2020;34(1): 101387. [Doi.org/10.1016/j.beem.2020.101387](https://doi.org/10.1016/j.beem.2020.101387)
26. Chen T, Wu D, Chen H, et al (2020). Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ (Clinical research ed.)*, 368:m1091. [Doi. org/10.1136/bmj.m1091](https://doi.org/10.1136/bmj.m1091)
27. Pearce EN, Farwell AP, Braverman LE (2003). Thyroiditis. *The New England journal of medicine*, 348(26), 2646–2655. [Doi.org/10.1056/NEJMra021194](https://doi.org/10.1056/NEJMra021194)
28. Desaillood R, Hober D. Viruses and thyroiditis: an update. *Virology journal*, 2009;6: 5. [Doi. org/10.1186/1743-422X-6-5](https://doi.org/10.1186/1743-422X-6-5)
29. Marazuela M, Giustina A, Puig-Domingo M. Endocrine and metabolic aspects of the COVID-19 pandemic. *Reviews in endocrine & metabolic disorders*, 2020;21(4):495–507. [Doi. org/10.1007/s11154-020-09569-2](https://doi.org/10.1007/s11154-020-09569-2)
30. Lisco G, De Tullio A, Stragapede A, et al. COVID-19 and the Endocrine System: A Comprehensive Review on the Theme. *Journal of clinical medicine*, 2021;10(13):2920. [Doi.org/10.3390/jcm10132920](https://doi.org/10.3390/jcm10132920)
31. Şahin Tekin M, Şaylısoy S, Yorulmaz G. Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: a case report. *Human vaccines & immunotherapeutics*, 2021;17(11): 4090–4092. [Doi.org/10.1080/21645515.2021.1947102](https://doi.org/10.1080/21645515.2021.1947102)
32. Scappaticcio L, Pitoian F, Esposito K, et al. Impact of COVID-19 on the thyroid gland: an update. *Reviews in endocrine & metabolic disorders*, 2021;22(4):803–815. [Doi.org/10.1007/s11154-020-09615-z](https://doi.org/10.1007/s11154-020-09615-z)
33. Hamburger JI. Subacute thyroiditis: diagnostic difficulties and simple treatment. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*, 1974; 15(2): 81–89
34. Dhakal BP, Sweitzer NK, Indik JH, et al. SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. *Heart, lung & circulation*, 2020;29(7):973–987. [Doi.org/10.1016/j.hlc.2020.05.101](https://doi.org/10.1016/j.hlc.2020.05.101)
35. Ruggeri RM, Campenni A, Siracusa M, et al. Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic. *Hormones (Athens, Greece)*, 2021;20(1): 219–221. [Doi.org/10.1007/s42000-020-00230-w](https://doi.org/10.1007/s42000-020-00230-w)
36. Hariyanto TI, Kurniawan A. Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection. *Diabetes & metabolic syndrome*, 2020;14(5):1429–1430. [Doi.org/10.1016/j.dsx.2020.07.044](https://doi.org/10.1016/j.dsx.2020.07.044)

37. Mateu-Salat, M., Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19. *Journal of endocrinological investigation*, 2020;43(10):1527–1528. Doi.org/10.1007/s40618-020-01366-7
38. Marazuela M, Giustina A, Puig-Domingo M. Endocrine and metabolic aspects of the COVID-19 pandemic. *Reviews in endocrine & metabolic disorders*,2020; 21(4):495–507. Doi.org/10.1007/s11154-020-09569-2
39. Tee LY, Harjanto S, Rosario BH. COVID-19 complicated by Hashimoto's thyroiditis. *Singapore medical journal*,2021; 62(5): 265. Doi.org/10.11622/smedj.2020106
40. Persani L, Brabant G, Dattani M, et al. 2018 European Thyroid Association (ETA) guidelines on the diagnosis and management of central hypothyroidism. *Eur Thyroid J*. 2018;7(5):225–37. Doi.org/10.1159/000491388.
41. de Vries EM, Fliers E, Boelen A. The molecular basis of the non-thyroidal illness syndrome. *The Journal of endocrinology*, 2015;225(3):R67–R81. Doi.org/10.1530/JOE-15-0133
42. Fliers E, Bianco AC, Langouche L, et al. Thyroid function in critically ill patients. *The lancet. Diabetes & endocrinology*,2015; 3(10): 816–825. Doi.org/10.1016/S2213-8587(15)00225-9
43. Van den Berghe G. Non-thyroidal illness in the ICU: a syndrome with different faces. *Thyroid : official journal of the American Thyroid Association*, 2014;24(10):1456–1465. Doi.org/10.1089/thy.2014.0201
44. Li, T, Wang L, Wang H, et al. Characteristics of laboratory indexes in COVID-19 patients with non-severe symptoms in Hefei City, China: diagnostic value in organ injuries. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*, 2020;39(12): 2447–2455. Doi.org/10.1007/s10096-020-03967-9
45. Li MY, Li L, Zhang Y,et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. *Infectious diseases of poverty*,2020; 9(1):45. Doi.org/10.1186/s40249-020-00662-x
46. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. *Cancer discovery*, 2020;10(6):783–791. Doi.org/10.1158/2159-8290.CD-20-0422
47. Tsang V, Gild,M, Glover A, et al. Thyroid cancer in the age of COVID-19. *Endocrine-related cancer*,2020; 27(11): R407–R416. Doi.org/10.1530/ERC-20-027
48. Smulever A, Abelleira E, Bueno F, et al. Thyroid cancer in the Era of COVID-19. *Endocrine*,2020; 70(1): 1–5. Doi.org/10.1007/s12020-020-02439-6
49. Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. *Cytokine & growth factor reviews*,2020; 53: 25–32. Doi.org/10.1016/j.cytogfr.2020.05.003
50. Java A, Apicelli AJ, Liszewski MK, et al. The complement system in COVID-19: friend and foe?. *JCI insight*, 2020;5(15): e140711. Doi.org/10.1172/jci.insight.140711
51. Boelaert K, Visser WE, Taylor PN, et al . ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism. *European journal of endocrinology*, 2020;183(1):G33–G39. Doi.org/10.1530/EJE-20-0445
52. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. *Lancet (London, England)*,2016; 388(10047): 906–918. Doi.org/10.1016/S0140-6736(16)00278-6
53. Chaker L, Bianco AC, Jonklaas et al. Hypothyroidism. *Lancet (London, England)*, 2017;390(10101): 1550–1562. Doi.org/10.1016/S0140-6736(17)30703-1
54. Léger, J, Olivieri A , Donaldson M., et al. ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAAE, & Congenital Hypothyroidism Consensus Conference Group. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. *The Journal of clinical endocrinology and metabolism*, 2014;99(2):363–384. Doi.org/10.1210/jc.2013-1891
55. Burch HB, Cooper DS . ANNIVERSARY REVIEW: Antithyroid drug therapy: 70 years later. *European journal of endocrinology*,2018; 179(5): R261–R274. Doi.org/10.1530/EJE-18-0678

56. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)*, 2020;395(10229): 1054–1062. Doi.org/10.1016/S0140-6736(20)30566-3
57. Ross DS, Burch HB, Cooper DS, et al. American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid : official journal of the American Thyroid Association*, 2016;26(10):1343–1421. Doi.org/10.1089/thy.2016.0229
58. Terpos E, Ntanasis-Stathopoulos I., Elalamy I, et al. Hematological findings and complications of COVID-19. *American journal of hematology*, 2020;95(7):834–847. Doi.org/10.1002/ajh.25829
59. Taylor PN, Zhang L, Lee R, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. *Nature reviews. Endocrinology*, 2020;16(2):104–116. Doi.org/10.1038/s41574-019-0305-4
60. Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. *European thyroid journal*, 2018;7(4):167–186. Doi.org/10.1159/000490384
61. Xia J, Tong J, Liu M., et al. (2020). Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. *Journal of medical virology*, 2020; 92(6):589–594. Doi.org/10.1002/jmv.25725